Using a modified virus and immune therapy for brain tumors
Oncolytic HSV Immunovirotherapy for brain tumors
['FUNDING_R01'] · MASSACHUSETTS GENERAL HOSPITAL · NIH-11136472
This research aims to improve treatment for glioblastoma, a serious brain cancer, by using a specially modified virus to destroy cancer cells and boost the body's immune response.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MASSACHUSETTS GENERAL HOSPITAL (nih funded) |
| Locations | 1 site (BOSTON, UNITED STATES) |
| Trial ID | NIH-11136472 on ClinicalTrials.gov |
What this research studies
Glioblastoma (GBM) is a very serious brain cancer that has been hard to treat effectively, with little improvement in survival over many years. This project focuses on a special type of herpes virus, called an oncolytic virus, which has been genetically changed to specifically target and destroy cancer cells while being safe for the human brain. The goal is to make this virus even more powerful by also stimulating the immune system within the tumor and reducing factors that suppress the immune response, such as adenosine. By combining direct viral attack with enhanced immune activity, we hope to find a more effective way to fight GBM.
Who could benefit from this research
Good fit: Patients with glioblastoma, particularly those whose tumors have shown resistance to current therapies, might be ideal candidates for future clinical trials based on this research.
Not a fit: Patients without glioblastoma or those with other types of brain tumors would not directly benefit from this specific treatment approach.
Why it matters
Potential benefit: If successful, this approach could offer a new and more effective treatment option for patients with glioblastoma, potentially improving their survival and quality of life.
How similar studies have performed: Previous work has shown that this type of modified herpes virus is safe and effective in the human brain for GBM, and this research aims to build upon that success by adding immune-boosting strategies.
Where this research is happening
BOSTON, UNITED STATES
- MASSACHUSETTS GENERAL HOSPITAL — BOSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MARTUZA, ROBERT L — MASSACHUSETTS GENERAL HOSPITAL
- Study coordinator: MARTUZA, ROBERT L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.